Profile: Jeffrey S. Barrett, Ph.D., FCP
Director, Laboratory for Applied PK/PD
-
Email: barrettj@email.chop.edu
Phone: 267-426-5479
Research Interests
Dr. Barrett was recruited to the division in 2003 to create a pharmacometric modeling and simulation center of excellence. His industrial experience in various clinical pharmacology settings provides a unique perspective to the division. Dr. Barrett is Research Associate Professor of Pediatrics and Director of the Laboratory for Applied PK/PD within the Division of Clinical Pharmacology and Therapeutics. He has served as the Laboratory Core Director for the CHOP Pediatric Pharmacology Research Unit from 2003-2005 and has assumed the role of Principal Investigator from Dr. Adamson in 2006. He received his B.S. from Drexel University in Chemical Engineering and his Ph.D. in Pharmaceutics from the University of Michigan. Prior to joining CHOP, Dr. Barrett spent 13 years in the pharmaceutical industry involved primarily with clinical PK/PD aspects of clinical drug development. Dr. Barrett has co-authored over 55 manuscripts and has given over 40 invited lectures on a variety of topics related to clinical drug development. He was elected to Fellow of the American College of Clinical Pharmacology (ACCP) in 2000 and was awarded the Tanabe Young Investigator Award in 2002. Dr. Barrett is the Chair for Clinical Sciences/AAPS and a Regent of the ACCP. He was elected as a Fellow of AAPS in 2004 and currently serves on the Clinical Pharmacology Advisory Committee to the US Food and Drug Administration.
Dr. Barrett's research is focused on investigating sources of variation in PK/PD with modeling and simulation strategies to develop rational dosing guidance for targeted (e.g. pediatric) populations. Clinical trial simulation is utilized prospectively to explore design dependencies and parameter sensitivities. Dr. Barrett also focuses on the development of pharmacometric approaches to advance PK-PD, novel biomarker development and disease progression modeling. His desire to return to academia was in part to better train the next generation of pediatric clinical pharmacologists in population modeling methodologies.